A citation-based method for searching scientific literature

Joshua A Beckman, Mark A Creager, Peter Libby. JAMA 2002
Times Cited: 1718







List of co-cited articles
355 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
11

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, S Kaptoge, E Di Angelantonio, E Ingelsson, D A Lawlor, E Selvin, M Stampfer,[...]. Lancet 2010
10

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
9

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.
Mark A Creager, Thomas F Lüscher, Francesco Cosentino, Joshua A Beckman. Circulation 2003
875
9


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
7

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
7

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
7

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
6


Oxidative stress and diabetic complications.
Ferdinando Giacco, Michael Brownlee. Circ Res 2010
5


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
5

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
5

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
5

Epidemiology of peripheral artery disease.
Michael H Criqui, Victor Aboyans. Circ Res 2015
667
5


Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis.
Michael A Gimbrone, Guillermo García-Cardeña. Circ Res 2016
4

Effect of a multifactorial intervention on mortality in type 2 diabetes.
Peter Gaede, Henrik Lund-Andersen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2008
4


Peripheral arterial disease in patients with diabetes.
Steven P Marso, William R Hiatt. J Am Coll Cardiol 2006
261
4

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
634
4


2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
4

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A Dormandy, Bernard Charbonnel, David J A Eckland, Erland Erdmann, Massimo Massi-Benedetti, Ian K Moules, Allan M Skene, Meng H Tan, Pierre J Lefèbvre, Gordon D Murray,[...]. Lancet 2005
4

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
700
4

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation.
Ghazaleh Behnammanesh, Zane E Durante, Kelly J Peyton, Luis A Martinez-Lemus, Scott M Brown, Shawn B Bender, William Durante. Front Pharmacol 2019
19
21

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.
Νarjes Nasiri-Ansari, Georgios K Dimitriadis, Georgios Agrogiannis, Despoina Perrea, Ioannis D Kostakis, Gregory Kaltsas, Athanasios G Papavassiliou, Harpal S Randeva, Eva Kassi. Cardiovasc Diabetol 2018
48
8

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
202
4

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
Sarah J Mancini, Daria Boyd, Omar J Katwan, Anastasiya Strembitska, Tarek A Almabrouk, Simon Kennedy, Timothy M Palmer, Ian P Salt. Sci Rep 2018
85
4

Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice.
Kentaro Mori, Kyoichiro Tsuchiya, Suguru Nakamura, Yasutaka Miyachi, Kumiko Shiba, Yoshihiro Ogawa, Kenichiro Kitamura. Cardiovasc Diabetol 2019
16
25



Atherosclerosis.
A J Lusis. Nature 2000
4


Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.
Yan Zheng, Sylvia H Ley, Frank B Hu. Nat Rev Endocrinol 2018
4

Clinical end points in coronary stent trials: a case for standardized definitions.
Donald E Cutlip, Stephan Windecker, Roxana Mehran, Ashley Boam, David J Cohen, Gerrit-Anne van Es, P Gabriel Steg, Marie-angèle Morel, Laura Mauri, Pascal Vranckx,[...]. Circulation 2007
3

Outcomes in Patients with Diabetes Mellitus According to Insulin Treatment After Percutaneous Coronary Intervention in the Second-Generation Drug-Eluting Stent Era.
Seung-Hoon Pi, Tae-Min Rhee, Joo Myung Lee, Doyeon Hwang, Jonghanne Park, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Jin-Ho Choi, Joo-Yong Hahn,[...]. Am J Cardiol 2018
16
18

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, William T Cefalu, James L Januzzi, Rita Rastogi Kalyani, Mikhail Kosiborod, Melissa L Magwire, Pamela B Morris,[...]. J Am Coll Cardiol 2018
174
3

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
305
3

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
281
3

Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis.
Alison Cameron-Vendrig, Adili Reheman, M Ahsan Siraj, Xiaohong Ruby Xu, Yiming Wang, Xi Lei, Talat Afroze, Eric Shikatani, Omar El-Mounayri, Hossein Noyan,[...]. Diabetes 2016
55
5

Platelet activation in type 2 diabetes mellitus.
P Ferroni, S Basili, A Falco, G Davì. J Thromb Haemost 2004
296
3

Diabetic Foot Ulcers and Their Recurrence.
David G Armstrong, Andrew J M Boulton, Sicco A Bus. N Engl J Med 2017
784
3

A new equation to estimate glomerular filtration rate.
Andrew S Levey, Lesley A Stevens, Christopher H Schmid, Yaping Lucy Zhang, Alejandro F Castro, Harold I Feldman, John W Kusek, Paul Eggers, Frederick Van Lente, Tom Greene,[...]. Ann Intern Med 2009
3

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.
Scott M Grundy, James I Cleeman, Stephen R Daniels, Karen A Donato, Robert H Eckel, Barry A Franklin, David J Gordon, Ronald M Krauss, Peter J Savage, Sidney C Smith,[...]. Circulation 2005
3

Diabetic neuropathies: a statement by the American Diabetes Association.
Andrew J M Boulton, Arthur I Vinik, Joseph C Arezzo, Vera Bril, Eva L Feldman, Roy Freeman, Rayaz A Malik, Raelene E Maser, Jay M Sosenko, Dan Ziegler. Diabetes Care 2005
3

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
3




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.